NCT04439201 2026-03-19Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)National Cancer Institute (NCI)Phase 2 Active not recruiting40 enrolled 9 charts